HMRC R&D tax credit
01 February 2024
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical
antibody discovery, engineering and supply for both therapeutic drug and
diagnostic applications, announces the receipt of an R&D tax
credit from HMRC in respect of the financial year ended 31 March 2023,
relating to work performed on the development and optimization of the
OptiMAL® platform, as well as other R&D projects in bioinformatics,
antigen design and cell culture. The value of the tax credit is in line
with expectations at almost £280k, which reflects the Company's
continued investment in R&D projects that maintain Fusion at the
forefront of technology in the antibody market. The technologies have
been well received by partners and potential partners with the OptiMAL®
platform notably undergoing validation through an agreement with the
National Cancer Institute in the USA. Fusion will maximise the impact of
the tax credit with the generation of revenue streams from the R&D
projects that were supported.
Adrian Kinkaid, CEO of Fusion, said: "The R&D tax credit system is of enormous benefit to companies developing cutting edge technologies such as we continue to do at Fusion. We are now beginning to reap the benefits of the resultant technology platforms with an elevated profile in our field and anticipate considerable commercial growth to be generated from them in the coming years."
Enquiries:
|
Fusion Antibodies plc |
www.fusionantibodies.com |
|
|
Adrian Kinkaid, Chief Executive Officer Stephen Smyth, Chief Financial Officer |
Via Walbrook PR |
|
|
|
|
|
|
Allenby Capital Limited |
Tel: +44 (0)20 3328 5656 |
|
|
James Reeve/Vivek Bhardwaj (Corporate Finance) Tony Quirke (Sales and Corporate Broking) |
|
|
|
|
|
|
|
Walbrook PR |
Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com |
|
|
Anna Dunphy |
Mob: +44 (0)7876 741 001 |
|
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO")
providing a range of antibody engineering services for the discovery and
development of antibodies for both therapeutic drug and diagnostic
applications.
The Company's ordinary shares were admitted to trading on AIM on 18
December 2017. Fusion provides a broad range of services in antibody
design, generation, development, production, characterisation and
optimisation. These services include antigen expression, antibody
production, purification and sequencing, antibody humanisation using
Fusion's proprietary CDRx TM platform and the
production of antibody generating stable cell lines to provide material
for use in clinical trials. Since 2012, the Company has
successfully sequenced and expressed over 250 antibodies and
successfully completed over 200 humanisation projects and has an
international, blue-chip client base, which has included eight of the
top 10 global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin out from Queen's University
Belfast. The Company's mission is to enable pharmaceutical and
diagnostic companies to develop innovative products in a timely and
cost-effective manner for the benefit of the global healthcare
industry.
Fusion Antibodies growth strategy is based on combining the latest
technological advances with cutting edge science to deliver new
platforms that will enable Pharma and Biotech companies get to the
clinic faster, with the optimal drug candidate and ultimately speed up
the drug development process.
The global monoclonal antibody therapeutics market was valued at $186
billion in 2021 and is forecast to surpass $445 billion in 2028, an
increase at a CAGR of 13.2 per cent. for the period 2022 to 2028.
Approximately 150 monoclonal antibody therapies are approved and
marketed globally as of June 2022 with the top four antibody drugs each
having sales of more than $3 bn in 2021.
